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OBJECTIVE: Our study aimed to monitor the trastuzumab therapy response of murine tumor xenograft model with
human epidermal growth factor receptor 2 (Her-2)–positive breast cancer using ultrasound targeted apoptosis
imaging.METHODS: We prepared targeted apoptosis ultrasound probes by nanobubble (NB) binding with Annexin
V. In vitro, we investigated the binding rate of NB–Annexin V with breast cancer apoptotic cells after the
trastuzumab treatment. In vivo, tumor-bearing mice underwent ultrasound targeted imaging over 7 days. After
imaging was completed, the tumors were excised to determine Her-2 and caspase-3 expression by
immunohistochemistry (IHC). The correlation between parameters of imaging and histologic results was then
analyzed.RESULTS: For seeking the ability of targetedNBbindingwith apoptotic tumor cells (Her-2 positive), we found
that binding rate in the treatment group was higher than that of the control group in vitro (P = .001). There were no
differences of tumor sizes in all groups over the treatment process in vivo (P= .98). However, when using ultrasound
imaging to visualize tumors by targetedNB in vivo, we observed that themean and peak intensities fromNBs gradually
increased in the treatment group after trastuzumab therapy (P = .001). Furthermore, these two parameters were
significantly associated with caspase-3 expression of tumor excised samples (P= .0001). CONCLUSION: Ultrasound
targeted apoptosis imaging can be a non-invasive technique to evaluate the early breast tumor response to
trastuzumab therapy.
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Breast cancer has become the most common cancer for female in
urban areas in China [1]. Among them, human epidermal growth
factor receptor 2 (Her-2)–positive breast cancers account to 25% to
30%, which have the characteristics of high invasion, early recurrence,
and metastasis [2,3]. Trastuzumab is a monoclonal antibody that
interferes with Her-2 and highly improves overall survival in late-stage
breast cancer [4]. However, the rapid development of drug resistance
after 1-year trastuzumab treatment and the high cost have limited its
usage [7,8].
To date, there are clinical and traditional imaging techniques
for the evaluation of trastuzumab therapy in patients with Her-
2–positive breast cancer [4]. However, the measurement of
tumor size by the clinical palpation and imaging examinations
will not always be good methods for the assessment of therapy
response [5,23]. Earlier assessment of trastuzumab effects on
Her-2–positive breast cancer before morphologic changes can
avoid exposing unnecessary possible side effects and costs from
this therapy. Before significant changes in tumor morphologic
alteration, histologic changes, such as tumor cell apoptosis, may
occur earlier during the treatment [6]. Thus, it would be of
considerable value for us to find a sensitive and non-invasive
method to evaluate the therapy response.
Molecular ultrasound imaging is a promising technique for
non-invasive evaluation of tumor response to anticancer
therapy, with the advantage of high spatial resolution, real-
time imaging, low cost, and lack of ionizing irradiation [9].
Generally, anticancer strategies can lead to cancer cell killing
and attenuate the tumor size, so that the non-invasive imaging
of cell death events, especially cell apoptosis, has the potential
predictive response to anticancer therapy [10]. An important
molecular marker for apoptosis is Annexin V, which is a
calcium-dependent phosphatidylserine-binding protein [11].
Ultrasound targeted imaging for apoptosis with Annexin V
would be of great value for imaging cancer cell early death
events. Thus, ultrasound molecular imaging targeted apoptosis
could be useful in monitoring trastuzumab treatment effect in
patients with Her-2–positive breast cancer. The aim of our
study is to explore a valuable ultrasound imaging method in a
preclinical model for the early assessment of breast cancer
targeted therapy.Figure 1. (A) The size distributions of targeted NBs were shown in the
were shown under the TEM (Philips EM400ST; scale bar, 1 μm).Materials and Methods
Cell Culture
The human breast cancer cell line SK-BR-3 (Her-2 positive),
obtained from the Chinese Academy of Sciences Cell Bank, was
cultured in Dulbecco's modified Eagle's medium, 10% FBS
(Hyclone), and 1% L-glutamine. The cell line was grown in a 5%
CO2 incubator at 37 °C. All cell number assays were determined with
a hemocytometer and trypan dye exclusion.
Targeted Nanobubble Preparation
Perfluoropropane-filled nanobubbles (NBs) were made from an
amphiphilic biomaterial, biotin–poly(ethylene glycol)–poly(lactic-co-
glycolic acid)–poly(ethylene glycol)–biotin. The poly(ethylene glycol)
and poly(lactic-co-glycolic acid) were obtained from Rebone and
Daigang Biomaterials Company (Shanghai, China). Briefly, biotin–
poly(ethylene glycol)–poly(lactic-co-glycolic acid)–poly(ethylene gly-
col)–biotin was dissolved in dichloromethane at a final concentration
of 100 mg/ml. The solution was poured into physiological saline
(0.9%) and stirred at 10000 rpm for 5 minutes to acquire solution A.
Solution A was subsequently poured into polyvinyl alcohol (Hengrui
Chemical Industry Co, Ltd, Tianjin, China) aqueous solution (2.0 wt
%) and stirred at 10000 rpm under a vacuum to get rid of
dichloromethane. NB solution (1 mg/ml) was co-cultured with
streptavidin for 24 hours at 4°C to get streptavidin-coated NBs.
Targeted NBs were prepared by incubating these streptavidin-coated
NBs with biotinylated Annexin V (Annexin V, 67 kDa; Abcam,
Shanghai, China) at 4 °C for 20 minutes. Unconnected Annexin V
was removed by centrifugation. The NB power was required after
lyophilization and enveloped into a via filled with perfluoropropane.
Before usage, the NBs were diluted using physiological saline (0.9%)
to a total volume of 1.0 ml and a concentration of 50 mg/ml. A
dynamic light scattering particle size analyzer (Brookhaven,
INNDVO300/BI900AT) was used to determine the size of NBs.
The mean diameter of NBs was 586 ± 6.0 nm (Figure 1).
In Vitro Studies
In the in vitro study, breast cancer SK-BR-3 cells were plated at 1 ×
106 cells onto six-well plates for 24 hours. Treatment group was
administrated by 20 μl of trastuzumab (10 μg/ml), and the control
one was treated with 20 μl of phosphate-buffered saline for 30line graph (mean diameter of NB, 586 ± 6.0 nm). (B) The NB images
Figure 2. The time line demonstrated the experimental processes of the time points, when we performed tumor implantation (lasting for
14 days), anti–Her-2 drug dosing (day 1), contrast ultrasound targeted imaging (days 3, 5, and 7), and tumor extraction (day 8).
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at room temperature overnight. Fluorescein isothiocyanate (FITC)–
labeled Annexin V–NBs (purchased from Abcam; 5 × 106 NB per
well) were incubated with SK-BR-3 cells (3 × 105 NB per well) in a
5% CO2 incubator at 37°C for 60 minutes. SK-BR-3 cells were fixed
with 4% polysorbate (Tianjin Umbrella Science and Technology, Co,
Ltd, Tianjin, China) for 15 minutes and washed with phosphate-Figure 3. (A) In vitro data showing caspase-3 expressions in the trea
counts (***P b .01). (B) This figure demonstrated the fluorescence
(b and f), and FITC–Annexin V–NB attached to SK-BR-3 cell (c and g)
control groups (scale bar, 10 μm). The binding rate of apoptotic cells
control groups was calculated according to the methods mentionedbuffered saline three times and then blocked out by 5% BSA (Tianjin
Umbrella Science and Technology, Co, Ltd) overnight.
The binding rates of FITC–Annexin V–NB with apoptotic cells
were calculated under a fluorescence microscope. Meanwhile, cell
nuclei co-stained with 4,6-diamidino-2-phenylindole (DAPI) were
shown in Figure 3B, and cells with pyknosis or lumpy nucleus
fragments were considered as apoptosis. For calculating binding rate,tment and control groups with flow cytometric mean fluorescent
microscope images of SK-BR-3 cell (a and e), FITC–Annexin V–NB
and cell nucleus stained with DAPI (d and h) in the treatment and
(d and h) with FITC–Annexin V–NB attached in the treatment and
.
Figure 4. (A) There was no significant difference in tumor sizes from day 0 to day 7 in the treatment and control groups (P= .98), indicating
that tumor size was not an indicator in early tumor response to anti–Her-2 drug. (B, C) TIC results showed that there were significantly
stronger mean and peak intensities in the treatment group detected by targeted NBs (T1 group) compared to those in the other three
groups (T2, C1, and C2 groups; P = .001; T1 group: the treatment group with NB–Annexin V; C1 group: the control group with NB–
Annexin V; T2 group: the treatment group with NB-IgG (non-targeted NB); C2 group: the control group with NB-IgG).
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were seen as positive in our study. Then, cells were stained by using
caspase-3 antibody (Santa Cruz Biotechnology, Inc, Dallas, TX) by
immunohistochemistry (IHC) to mark apoptotic cells. The apoptotic
cells were analyzed by fluorescent counts using flow cytometry
(Gallios Flow Cytometer; Beckman Coulter, Inc, Brea, CA).
Animal Preparation and In Vivo Studies
Animal experiments were approved by the Institutional Ethical
Board of Tianjin Cancer Hospital (Tianjin, China). BALB/c nude
mice were obtained from Tianjin Medical University (Tianjin,
China). As a preparatory experiment, SK-BR-3 cells (2 × 106) were
implanted in two mammary fat pads of each mouse (n = 2). The two
different diameters (a and b) of tumors were measured, and the tumor
volumes were calculated by the formula V = ab2/2. The duration
time lasted 2 weeks after implantation. Xenograft tumors (n = 20; the
mean diameter was 6.1 ± 0.6 mm) in 10 mice were used for
measuring the distribution of tumor vascular endothelial gaps. The
mice were anesthetized with 0.5% pentobarbital sodium through
intraperitoneal route. The tumors were extracted and fixed in 3%
paraformaldehyde and 1% glutaraldehyde for 48 hours at 4°C. The
samples (0.9 ± 0.06 mm3) were embedded in Epon 812 (Haide
Biotech Company, Beijing, China) and then sliced into 50-nm
sections by ultramicrotome. The slices were observed to measure the
size of gaps between tumor endothelial cells under a transmission
electron microscope (TEM; Philips EM400ST).
In our following study, 40 mice were separated into four different
groups (n = 10 per group). Treatment groups were T1 (trastuzumabtreated + NB–Annexin V) and T2 (trastuzumab treated + NB-IgG);
the control groups were C1 (NB–Annexin V only) and C2 (NB-IgG
only). After a 14-day implantation (the mean diameter was 6.4 ± 0.7
mm; the average tumor size was 139.7 ± 5.2 mm3), targeted NBs
were intravenously injected (1 × 108 NBs per mouse in a 0.1-ml dose
consisting of 0.05 ml of NBs and 0.05 ml of saline) in the tail vein
(T1 and C1 groups) after the treatment.
Treatment Protocol
Trastuzumab (Herceptin; Genentech, South San Francisco, CA)
was given to two treatment groups on day 1. The dosage was 0.5 mg
(20 mg/kg) diluted with saline to 200 μl through intraperitoneal
injection for each mouse in the treatment groups (T1 and T2 groups).
Control groups (C1 and C2 groups) received a 200-μl intraperitoneal
dose of saline.
Ultrasound Molecular Imaging
Ultrasound targeted imaging was performed in vivo on day
0 for baseline scanning and after the treatment for 3 days at
three different times (days 3, 5, and 7) and was repeated three
times a day (1, 6, and 12 hours; Figure 2). The skin above or
around the tumor was shaved before imaging session. After mice
were anesthetized, ultrasound imaging was performed with an
iU22 scanner (Phillip Medical Systems, Andover, MA) using an
L12-5 high-frequency linear transducer for grayscale imaging and
an L9-3 transducer for contrast ultrasound imaging. Contrast
dual-image model settings were optimized as follows: mechanical
index was 0.06 and the frame rate was 11 Hz. The ultrasound
Figure 5. (A) On day 0, contrast ultrasound dual-image mode showed the baseline scanning (left: a contrast image; right: a grayscale
image). From day 3 to day 7, ultrasound contrast imaging (60 minutes after NB injection) demonstrated a significant increase in the
intratumoral perfusions (double red arrow showing) in the treatment group with NB–Annexin V (T1 group) (a) compared to those in the
other three groups (T2, C1, and C2 groups) (b, c, and d). On day 8, the mouse tumors were excised and then stained by caspase-3
antibody (tumor cells immunostained brown and original magnification, ×200). This figure also showed the positive correlation between
NB perfusions in these groups and caspase-3–positive expressions in tumor samples. (B) The contrast ultrasound dual image (left: a
grayscale image; right: a contrast image) showed that ROI was an irregular red area within the mouse tumor (the figure above). TIC
(the figure below) indicated that the peak intensities of ROI were 42.5± 4.8 dB and the mean intensities were 35.2 ± 3.5 dB, which were
calculated by the QLAB software.
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transverse cross section. At least three probe planes were used to
present tumors for calculating tumor volumes.
A dose of 100 μl targeted contrast agents diluted by saline was
intravenously injected through the tail vein. Thirty seconds after the
injection, contrast harmonic imaging was acquired to observe the
contrast echoes from NBs. Ultrasound transmission was then paused
for 60 minutes to allow targeted NBs to bind with apoptotic cells at
targeted sites. The whole imaging process lasted 180 seconds to
capture tumor perfusion of NB agents and was recorded on the hard
disk of the scanner for post-imaging review. Images were then saved in
the DICOM format. The regions of interests (ROIs) were given as thewhole areas of tumors and analyzed by the QLAB software
(Figure 5B). The change in NB signal intensity, the size of perfusion
areas, and other parameters (arrival time, time to peak, and area under
the curve) of the time-intensity curve (TIC) were also uploaded to
QLAB for analysis. The average intensity of NBs was repeated three
times at each point over the entire protocol. We calculated changes of
these parameters before and during the study to compare their
differences statistically.
IHC and Imaging Comparison
At the end of the protocol (day 8), mice were killed, and tumor
samples were excised, fixed in formalin solution, embedded in
Figure 6. (A) Comparing the peak or mean intensities with the percentage of caspase-3–positive expressions in mouse tumors among
these four groups, the data demonstrated significant correlations among these parameters (r = 0.78, P = .038; r = 0.69, P =.042,
respectively). (B) The percentage of Her-2 and caspase-3–positive expressions in mouse tumors among the four groups showed that
there was an adverse trend between Her-2 expressions and caspase-3 expressions during the anti–Her-2 drug treatment. This figure
indicated that there have been tumor responses for anti–Her-2 drug therapy in vivo, which led to tumor Her-2 expressions decreasing and
tumor cell apoptosis increasing (T1 group: the treatment group with NB–Annexin V; C1 group: the control group with NB–Annexin V; T2
group: the treatment group with NB-IgG (non-targeted NB); C2 group: the control group with NB-IgG.)
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Samples were stained by hematoxylin and eosin to visualize the tumor
necrosis within different groups. The anti-murine caspase-3 p11
antibody (Santa Cruz Biotechnology, Inc) was used for histochem-
istry to detect the cell apoptosis in tumors (Figure 5A).
The immunoreaction for caspase-3 and Her-2 (anti–Her-2
antibody; Abcam) in tumor cells was determined by two pathologists
(P.Y. and C.R.F.), and the consensus was reached for the final
diagnosis. The scores and percentage of tumor cells stained are
described as follows [5,6]: no positive cells (−), 1% to 10% of the cells
stained (+), 11% to 50% of cells stained (++), and 51% to 100% of
the cells stained (+++). We then calculated the percentage of number
of mice with positive caspase-3 and Her-2 expression in each group
and described them by bars. Comparison with the average mean and
peak NB intensities analyzed by the software after the treatment was
carried out to find the correlation between NB intensities and IHC
results.
Statistical Analysis
Statistical analyses were performed with SPSS statistical software
package (17.0 version; SPSS Inc, Chicago, IL). Data were
summarized as means ± standard error. In vitro, count data were
analyzed in the assessment of the intergroup comparison with a two-
sample independent t-test. Analyses of mouse weight and tumor size
or parameters of ultrasound imaging were compared between groups
with multiple comparison in analysis of variance (Student-Newman-
Keuls test or least significant difference procedure test). A correlation
between histologic and imaging experimental data was performed
by Pearson correlation test. A P value below .05 was considered
significant.
Results
Characteristic of NBs and In Vitro Experiment
As Figure 1B showed, the NBs prepared before was well distributed
and uniformed, which was described as a normal distributed curve
(Figure 1A), and the mean sizes of NB was 586 ± 6.0 nm.
After the trastuzumab administration, the binding rate of targeted
NB with human breast cancer apoptotic cells was higher than that of
the control group (79.2 ± 3.3% vs 9.2 ± 1.7%, P = .001; Figure 3B).
The average number of cells with caspase-3 expression in the
treatment group increased significantly compared to that of thecontrol one [(82.6 ± 3.5) × 103 and (21.4 ± 2.3) × 103, respectively;
Figure 3A].
In Vivo Experiment and Histologic Analysis
All mice were alive during the whole experiment. In the
preparatory study, we observed the tumor slices under the TEM
and calculated the mean sizes of gaps between vascular endothelial
cells (865 ± 5.2 nm; range, 630-1325 nm) for 20 xenograft tumors.
This result indicated that average gap sizes between tumor vascular
endothelial cells were larger than our NB mean sizes (586 ± 6.0 nm)
in our mouse model.
As the time line in Figure 2 showed, we processed the following
experiment and observed that there were no statistical differences in
the average weights of mice within four groups on day 0 (P = .76) and
day 7 (P = .79). As for tumor sizes, the data indicated no differences
among four groups from day 0 to day 7 during the whole treatment
process (P = .98; Figure 4A). Histologic analysis showed that there
were no significant differences in the percentage of necrotic areas of
samples between treatment (TI and T2) and control groups (C1 and
C2; P = .21). At the end of treatment, anti–Her-2 therapy response
was investigated by IHC analyses of Her-2 and caspase-3 expression
in excised tumors. The data showed that the percentages of Her-2–
positive expression in mouse tumors in the two treatment groups (TI
and T2; 54.5% and 66.7%) were lower than the control ones (91.2%
and 80%, respectively; Figure 6B). This indicated that there was
effective treatment in mouse xenograft models (T1 and T2 groups)
and the trastuzumab treatment also induced apoptosis cells in these
tumors. Thus, the percentages of caspase-3–positive expression in
mouse samples in the two treatment groups (TI and T2) were higher
than those of the control groups (C1 and C2; 90.0% and 83.3% vs
66.7% and 70%, respectively; Figure 6A).
Ultrasound Targeted Imaging and Histologic
Result Correlation
The ultrasound contrast imaging detected NB signals in in vivo
models after 60 minutes from the injection of NB through the mouse
tail vein, and this process was carried out under different time points
(days 0, 3, 5, and 8; Figure 5A). Then, ultrasound imaging software
analyses indicated that the average mean intensities of targeted
bubbles in ROIs (Figure 5B) in the T1 group were significantly
higher than those in the other three groups (T2, C1, and C2; P =
.001; Figure 4C). However, there were no differences within the three
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other three groups (T2 vs T1 + C1 + C2, P = .74; C1 vs T1 + T2 +
C2, P = .51, and C2 vs T1 + T2 + C1, P = .33, respectively). As for
peak intensities of intratumor microbubble perfusion, they were also
higher in the T1 group than those in the other groups (T2, C1, and
C2; P = .00), but there were no differences within T2, C1, and C2
groups (P = .43, .96, and .42, respectively; Figure 4B). The
correlations between the mean and peak intensities of ultrasound
imaging and caspase-3 expression of the tumor samples were
statistically significant in all four groups after the treatment (r =
0.78, P = .038; r = 0.69, P = .042, respectively; Figures 5A and 6A).
Discussion
Trastuzumab has been used in the treatment of Her-2–positive
metastatic breast cancer over one decade [4,7,8]. Although it has great
affinity for Her-2 and low toxicity, about 70% of patients do not
respond to this treatment [12]. Therefore, early identification of
patients who would benefit from trastuzumab can avoid additional
cost for patients [6]. Traditional imaging and fluorescent in situ
hybridization have been viewed as the “gold standard” techniques for
predicting the treatment response, but they are expensive and not
real-time systems [4,13,14]. Our study intended to investigate the
usage of ultrasound molecular imaging techniques to evaluate the
response to trastuzumab therapy in Her-2–positive breast cancer in
the tumor xenograft model.
Dynamically monitoring the tumor inner change, such as tumor
cell apoptosis during treatment, could be an early indicator of breast
cancer response to trastuzumab [15]. An apoptosis marker, Annexin
V, has been labeled with FITC and coupled to magnetic nanoparticles
to identify apoptotic cells [22,24]. In addition, there were various
methods to design targeted apoptosis probes to detect tumor cell
apoptosis. Previous studies used biotin/streptavidin interactions to
conjugate targeting ligands, such as αvβ3 integrin, P-selectin, or
vascular endothelial growth receptor 2, to image tumor angiogenesis,
or to evaluate the antiangiogenic therapy response of tumors [16–18].
In our targeted apoptosis NB design, streptavidin-based bubbles
binding to biotin–Annexin V were also used to dynamically detect
tumor apoptotic cells during treatment in vitro and in vivo. These
targeted bubbles with nanolevel diameters (less than 600 nm) can
easily pass through the gaps between the tumor's new microvascular
endothelial cells (865 ± 5.2 nm, tested in the preparatory study) to
adhere to the surface of tumor apoptotic cells in our tumor xenograft
model. In the imaging study, we tested signals of NBs at 60 minutes
after the injection. According to previous reports [17,19], it would be
of enough time for bubbles to bind to tumor cells through vessels.
Thus, it is possible for us to use these targeted NBs to detect tumor
apoptotic cells in vivo.
First, for seeking the binding ability of targeted NB with targeted
cells in vitro, we found that NB–Annexin V bound to trastuzumab-
treated cells significantly better than to control (buffer-treated) cells,
which is confirmed by DAPI-stained nucleus test and caspase-3–
positive expression. After preparing the breast cancer–bearing mice,
we performed ultrasound targeted imaging to assess the early response
to anti–Her-2 drugs in breast cancer. We noted that the change of
tumor sizes has no difference between treatment groups and control
ones during the whole experiment. However, targeted apoptosis NB
intensities in tumors (mean and peak intensity) detected by
ultrasound contrast imaging became stronger after the anti–Her-2
drug treatment. This phenomenon indicated that tumor cellapoptosis scanned by ultrasound targeted apoptosis imaging
happened earlier than the change of tumor size during the treatment.
For further investigating the anti–Her-2 drug efficiency, we stained
all excised tumors in the four groups by anti–Her-2 antibody. The
results showed that there was lower Her-2–positive percentage in
mouse tumors among treatment groups than that in control groups.
This indicated that breast tumors in vivo have good pathologic
response to the anti–Her-2 drug. Furthermore, our ultrasound
imaging results facilitated the detection of tumor response of
trastuzumab before excising mouse tumors.
Moreover, our study also demonstrated that the intensity of
targeted NBs was significantly associated with caspase-3 expressions
of tumor samples at the end of experiment. Therefore, ultrasound
targeted imaging with NB–Annexin V could be a good tracer to
indicate cell apoptosis events and early prediction of trastuzumab
therapy outcome in breast cancer. In addition, a large number of data
strongly suggested that apoptosis in tumors after treatment happened
earlier than cell proliferation and glucose metabolism did [9,20,21].
Thus, targeted apoptosis molecular imaging could be a feasible
indicator for therapy response of tumors.
In conclusion, targeted apoptosis ultrasound imaging will be a
promising and non-invasive technique to the early prediction of
breast cancer response to anti–Her-2 therapy. More targeted
ultrasound imagings should be investigated to early evaluate the
therapy outcome of cancers on the platform of ultrasound molecular
imaging.
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